David Tsao Sells 10,000 Shares of Billiontoone (NASDAQ:BLLN) Stock

Billiontoone, Inc. (NASDAQ:BLLN) CTO David Tsao sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $100.00, for a total value of $1,000,000.00. Following the sale, the chief technology officer owned 1,000 shares of the company’s stock, valued at approximately $100,000. This trade represents a 90.91% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

David Tsao also recently made the following trade(s):

• On Monday, August 10th, David Tsao sold 10,000 shares of Billiontoone stock. The shares were sold at an average price of $92.86, for a total value of $928,600.00.
• On Monday, June 15th, David Tsao sold 20,000 shares of Billiontoone stock. The shares were sold at an average price of $102.27, for a total value of $2,045,400.00.

Billiontoone Stock Down 2.0%

BLLN stock opened at $93.24 on Friday. The company has a current ratio of 11.69, a quick ratio of 11.31 and a debt-to-equity ratio of 0.17. The firm has a 50 day simple moving average of $115.10 and a 200-day simple moving average of $95.27. The company has a market capitalization of $4.40 billion and a P/E ratio of 133.20. Billiontoone, Inc. has a twelve month low of $61.96 and a twelve month high of $150.44.

Billiontoone (NASDAQ:BLLN) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $0.15 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.15. Billiontoone had a net margin of 8.04% and a return on equity of 9.96%. The firm had revenue of $109.45 million for the quarter. On average, equities research analysts predict that Billiontoone, Inc. will post 0.83 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently commented on BLLN shares. JPMorgan Chase & Co. reduced their price target on shares of Billiontoone from $145.00 to $130.00 and set an “overweight” rating on the stock in a research report on Thursday, August 6th. Weiss Ratings upgraded Billiontoone from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday, June 23rd. BTIG Research reduced their target price on Billiontoone from $142.00 to $130.00 and set a “buy” rating on the stock in a report on Thursday, August 6th. Wall Street Zen lowered Billiontoone from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Finally, Guggenheim started coverage on Billiontoone in a report on Monday, June 29th. They issued a “buy” rating and a $125.00 price target for the company. Six investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $126.71.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Rossby Financial LCC bought a new stake in shares of Billiontoone during the 4th quarter valued at about $25,000. Wells Fargo & Company MN bought a new position in Billiontoone in the fourth quarter worth about $76,000. Smartleaf Asset Management LLC acquired a new position in Billiontoone in the fourth quarter valued at approximately $80,000. Nano Cap New Millennium Growth Fund L P acquired a new position in Billiontoone in the fourth quarter valued at approximately $82,000. Finally, Caitong International Asset Management Co. Ltd bought a new position in shares of Billiontoone during the fourth quarter valued at approximately $230,000.

Billiontoone Company Profile

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.